Search
for
Sort by
Research 31–60 of 775
- Upadacitinib Efficacy for the Treatment of Concomitant Psoriasis and Alopecia Areata
- Low-dose tofacitinib for treating patients with severe alopecia areata: an efficient and cost-saving regimen
- Upadacitinib for the treatment of alopecia areata – A case report
- Effective treatment of refractory alopecia areata in pediatric patients with oral abrocitinib
- Upadacitinib: A New Weapon for the Treatment of Twenty-Nail Dystrophy
- Good efficacy achieved by baricitinib in the treatment of anti-MDA5 antibody-positive dermatomyositis with alopecia areata
- The role of janus kinases in the treatment of autoimmune skin diseases
- Baricitinib Demonstrates Rapid Action Within Just 2 Months of Treatment in Severe and Unresponsive Alopecia Areata: A Case Report
- Successful hair regrowth in a Korean patient with alopecia universalis following tofacitinib treatment
- Ivarmacitinib in atopic dermatitis presenting with prurigo nodularis-like lesions and alopecia areata: a case report
- Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
- Upadacitinib for the Management of Alopecia Totalis and Subtotalis in Pediatric Patients: A Case Series
- Abrocitinib Improved Dupilumab-Resistant Severe Atopic Dermatitis with Comorbid Mild Alopecia Areata in a 12-Year-Old Boy: A Case Report with 1-Year Follow-Up
- Case report: Psoriasiform eczema with immune-mediated comorbidities treated with upadacitinib
- Janus Kinase inhibitors in dermatology: a review
- 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
- JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician
- JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
- JAK inhibitors in dermatology: The promise of a new drug class
- Under Development JAK Inhibitors for Dermatologic Diseases
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- JAK Inhibitors for Treatment of Alopecia Areata
- Janus Kinase Inhibitors in the Treatment of Alopecia Areata
- Small Molecule Inhibitors and Inflammatory Skin Diseases
- Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients
- Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis
- Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
- Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review
- JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis